PFO
ROIV icon

Pathstone Family Office’s Roivant Sciences ROIV Stock Holding History

Pathstone Family Office’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,488
Closed -$284K – 1304
2023
Q1 		$284K Sell
38,488
-38,488
-50% -$317K ﹤0.01% 936
2022
Q4 		$56.6K Hold
76,976
– – ﹤0.01% 1459
2022
Q3 		$248K Buy
76,976
+40,715
+112% +$158K ﹤0.01% 1278
2022
Q2 		$148K Buy
+36,261
New +$144K ﹤0.01% 975

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's ROIV Position: Q2 2023 in Review

Pathstone Family Office sold out of Roivant Sciences (ROIV) in Q2 2023, closing a stake of 38,488 shares — an estimated $284K sold.

Pathstone Family Office first reported a position in ROIV in Q2 2022 and held it in 4 quarters. The position peaked at $284K in Q1 2023. 181 funds tracked by Wall St. Rank hold ROIV as of Q2 2023.

  • Pathstone Family Office reported no remaining Roivant Sciences position as of Q2 2023 after selling out during the quarter.
  • Pathstone Family Office sold 38,488 Roivant Sciences shares in Q2 2023, an estimated $284K.
  • Pathstone Family Office first reported a position in Roivant Sciences in Q2 2022 and held it in 4 quarters.
  • Pathstone Family Office's Roivant Sciences position peaked at $284K in Q1 2023.
  • 181 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2023.

Based on Pathstone Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.